SLC25A41 Gene

SLC25A41 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC25A41 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SLC25A41</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 25 Member 41</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>19q13.42</td>
</tr>
<tr>
<td class="label">Gene ID</td>
<td>81886</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000166224</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y241</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>AAC4, APC4</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Mitochondrial Modulators</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Metabolic Enhancers</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">ANT1</td>
<td>Co-transporter</td>
</tr>
<tr>
<td class="label">Phosphate Carrier</td>
<td>Coupling</td>
</tr>
<tr>
<td class="label">VDAC</td>
<td>Metabolite channel</td>
</tr>
<tr>
<td class="label">Hsp70</td>
<td>Chaperone</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

SLC25A41 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC25A41 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SLC25A41</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 25 Member 41</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>19q13.42</td>
</tr>
<tr>
<td class="label">Gene ID</td>
<td>81886</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000166224</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y241</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>AAC4, APC4</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Mitochondrial Modulators</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Metabolic Enhancers</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">ANT1</td>
<td>Co-transporter</td>
</tr>
<tr>
<td class="label">Phosphate Carrier</td>
<td>Coupling</td>
</tr>
<tr>
<td class="label">VDAC</td>
<td>Metabolite channel</td>
</tr>
<tr>
<td class="label">Hsp70</td>
<td>Chaperone</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Slc25A41 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

SLC25A41 Gene is an important protein/gene involved in various neurological processes. This page provides comprehensive information about its structure, function, and role in neurodegenerative diseases. [@mitochondrial]

The SLC25A41 gene encodes a mitochondrial carrier protein that transports ADP/ATP across the inner mitochondrial membrane. This protein is part of the mitochondrial carrier family (SLC25) and plays a critical role in cellular energy metabolism by facilitating the exchange of mitochondrial ATP for cytosolic ADP. The protein is essential for oxidative phosphorylation and cellular energy homeostasis. [@energy]

Gene Information

Protein Structure

SLC25A41 is a mitochondrial carrier protein with characteristic features:

Transmembrane Architecture

• 6 Transmembrane α-Helices: Form the transport channel
• Mitochondrial Carrier Domain: Signature sequence motifs
• Triple Sequence Repeats: Characteristic of SLC25 family

Functional Sites

• Substrate-binding Site: Central cavity for ADP/ATP
• Binding Cassettes: Three repeated motifs
• Matrix and Intermembrane Space Portals: Entry and exit gates

Function

Mitochondrial ADP/ATP carrier (AAC4) has essential functions:

Transport Mechanism

Energy Metabolism

• Oxidative Phosphorylation: Essential for ATP production
• Cellular Respiration: Couples electron transport to ATP synthesis
• Mitochondrial Function: Key component of OXPHOS
• Cytosolic Energy Supply: Provides ATP for cellular processes

Regulatory Properties

• Inhibition: Inhibitors include atractyloside and bongkrekic acid
• Activation: Phosphate carrier coupling
• Metabolic Regulation: Substrate availability

Expression Pattern

Tissue Distribution

• Heart: Highest expression (high energy demand)
• Brain: [Neurons](/entities/neurons), especially high in motor neurons
• Skeletal Muscle: High energy demand tissues
• Kidney: Moderate expression

Cellular Localization

• Inner Mitochondrial Membrane: Integral membrane protein
• Mitochondrial Matrix: C-terminus faces matrix
• Intermembrane Space: N-terminus faces IMS

Brain Regional Expression

• Motor [Cortex](/brain-regions/cortex): Motor neuron populations
• Spinal Cord: Motor neurons (vulnerable in ALS)
• Basal Ganglia: Dopaminergic neurons
• [Hippocampus](/brain-regions/hippocampus): Pyramidal neurons

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

• SLC25A41 variants implicated in ALS risk
• Motor neurons have high energy demands
• Mitochondrial dysfunction in ALS pathogenesis
• Energy metabolism deficits in motor neurons
• May interact with known ALS genes

Parkinson's Disease

• Altered mitochondrial carriers in PD
• Complex I deficiency affects energy metabolism
• Possible interaction with PINK1/Parkin pathway
• Dopaminergic neurons are energy-intensive
• Mitochondrial quality control defects

Stroke and Ischemia

• Mitochondrial energy failure in ischemic injury
• AAC4 function impaired during ischemia
• Potential therapeutic target
• Reperfusion injury involves mitochondrial dysfunction

Other Conditions

• Metabolic Disorders: Diabetes, obesity
• Cardiovascular Disease: Heart failure
• Aging: Declining mitochondrial function

Therapeutic Implications

Targeting Strategies

Neurodegeneration

• Enhancing mitochondrial function
• Protecting energy-depleted neurons
• Supporting motor neuron survival

Interaction Network

Research Directions

• Understanding genetic variants in neurodegeneration
• Developing mitochondrial-targeted therapeutics
• Biomarker potential: SLC25A41 as disease marker

Background

The study of Slc25A41 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [SLC25A20 Gene - Carnitine-acylcarnitine translocase](/institutions/cas)
• [SLC25A4 Gene - ANT1](/genes/slc25a4)
• [Mitochondrial Function](/clinical-trials/physical-activity-mitochondrial-function-pd-nct05963425)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Energy Metabolism](/companies/ad-ampk-activator-energy-metabolism-companies)

External Links

• [NCBI Gene: SLC25A41](https://www.ncbi.nlm.nih.gov/gene/81886)
• [UniProt: Q9Y241](https://www.uniprot.org/uniprot/Q9Y241)
• [SLC25A41 - GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC25A41)

References